Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel

We evaluated whether treatment of orthotopic human prostate cancer in nude mice with pegylated IFN-alpha-2b (PEG-IFN-alpha-2b) and docetaxel could represent a two-compartment targeting of primary tumor (tumor cells and tumor-associated endothelial cells) and inhibition of regional lymph node metasta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2002-10, Vol.62 (20), p.5720
Hauptverfasser:	Huang, Samuel F, Kim, Sun-Jin, Lee, Anh T, Karashima, Takashi, Bucana, Cora, Kedar, Daniel, Sweeney, Paul, Mian, Badar, Fan, Dominic, Shepherd, David, Fidler, Isaiah J, Dinney, Colin P, Killion, Jerald J
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - pharmacology Animals Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - pharmacology Antineoplastic Combined Chemotherapy Protocols - pharmacology Cadherins - biosynthesis Cell Division - drug effects Dose-Response Relationship, Drug Drug Synergism Fibroblast Growth Factor 2 - biosynthesis Humans Immunohistochemistry Interferon-alpha - administration & dosage Interferon-alpha - pharmacology Male Matrix Metalloproteinase 2 - biosynthesis Matrix Metalloproteinase 9 - biosynthesis Mice Mice, Nude Neoplasm Metastasis - prevention & control Paclitaxel - administration & dosage Paclitaxel - analogs & derivatives Paclitaxel - pharmacology Polyethylene Glycols - administration & dosage Polyethylene Glycols - pharmacology Prostatic Neoplasms - blood supply Prostatic Neoplasms - drug therapy Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Random Allocation Recombinant Proteins Taxoids Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!